Evofem Biosciences to Participate in Four Upcoming Investor Conferences
08/31/2020 - 09:00 AM
SAN DIEGO , Aug. 31, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM), a commercial-stage biopharmaceutical company, today announced it will participate in four healthcare equity conferences in September:
H.C. Wainwright & Co. 22nd Annual Global Investment Conference: presentation on Monday, September 14, 2020 from 3:30 to 3:50 p.m. EST . 2020 Cantor Global Virtual Healthcare Conference: virtual fireside chat on Wednesday, September 16, 2020 from 4:00 p.m. to 4:30 p.m. EST . Morgan Stanley 18th Annual Global Healthcare Conference: virtual fireside chat onFriday, September 18, 2020 from 11:00 a.m. to 11:30 a.m. EST . Oppenheimer Fall Healthcare Life Sciences & MedTech Summit: virtual fireside chat onTuesday, September 22, 2020 from 10:50 a.m. to 11:30 a.m. EST .To access the live and archived webcasts of these presentations, visit the Investors section of the Evofem Biosciences website at www.evofem.com , and select the Events and Presentations tab.
About Evofem Biosciences, Inc. Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company's first commercial product, Phexxi™ (lactic acid, citric acid and potassium bitartrate), is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company is also advancing EVO100 into Phase 3 clinical trials for the prevention of urogenital transmission of both Chlamydia trachomatis infection (chlamydia) and Neisseria gonorrhoeae infection (gonorrhea) in women. For more information, please visit www.evofem.com .
Phexxi™ is a trademark of Evofem Biosciences, Inc.
Investor Contact Amy Raskopf Evofem Biosciences, Inc.araskopf@evofem.com M: (917) 673-5775
Media Contact Becky Vonsiatsky W2O Group bvonsiatsky@w2ogroup.com M: (413) 478-2003
View original content to download multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-to-participate-in-four-upcoming-investor-conferences-301120737.html
SOURCE Evofem Biosciences, Inc.
EVFM Rankings
N/A Ranked by Stock Gains
EVFM Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
Country
US
City
San Diego
About EVFM
evofem is a biotechnology company focusing on developing innovative reproductive health products for women in every global market. evofem develops and markets products that are woman-controlled, non-invasive and rapidly reversible. women need access to effective products that are well suited to their lifestyle and consistent with their core values. products include: amphora™ - a non-hormonal vaginal gel being investigated for contraceptive and microbicidal properties.